MiNK Therapeutics, Inc. (INKT) is in Healthcare, Biotechnology, based in United States, listed on NasdaqCM. Market cap 56.13M USD. 52-week range 8.48 to 16.93 USD. Data as of 2026-10-09.
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and ...